Both the PI3K/AKT and Wnt/b-catenin signaling pathways modulate the CSC phenotype in endometrial cancer [116]; thus, YY1 might regulate the CSC phenotype, leading to worse clinical outcomes. This evidence concerns the gene YY1 and endometrial cancer.